Starpharma rockets on cancer drug hope

23 September 2017

The Herald Sun noted strong investor interest and support for Starpharma regarding its positive phase 1 DEP® docetaxel trial and that no neutropenia was reported in any patients.

Go to article


About Starpharma

This document contains Forward Looking Statements

For Further Information


© Starpharma Holdings Limited 2017